Epidermal growth factor receptor (EGFR) mutations in NSCLC

Slides:

Advertisements

Similar presentations

© 2005 Prentice Hall Inc. / A Pearson Education Company / Upper Saddle River, New Jersey Lung Cancer and Gefitinib  Lung cancer statistics in the.

Advertisements

EGFR exon 20 insertion mutations

Defining Epidermal Growth Factor Receptor exon 20 mutant sensitivity to tyrosine kinase inhibition Danny Rayes.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Management of asthma exacerbations: emergency department and hospital-based treatment. (Adapted from National Asthma Education and Prevention Program.

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Large cell undifferentiated carcinoma of lung

(Copied with permission from: Latson, L. A. , & Prieto, L. R. (2007)

Defining Epidermal Growth Factor Receptor exon 20 mutant sensitivity to tyrosine kinase inhibition Danny Rayes.

Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Fig. 2. High-resolution melting curves for exon 21 of the EGFR gene

Nine patterns of inflammatory skin disease. (See also Table 8–1.)

Diagnostic algorithm for normocytic anemia.

Stage IV non–small cell lung cancer (NSCLC)

Hypothetical distribution of test results for healthy and diseased individuals. The position of the "cutoff point" between "normal" and "abnormal" (or.

Structures of antiestrogens and aromatase inhibitors

Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy.

Schematic comparison of structural features of cell surface growth factor receptor tyrosine kinases and membrane-associated tyrosine kinase oncogene products.

Radiation-induced pulmonary fibrosis

Average annual number of dengue fever/dengue hemorrhagic fever cases reported to the World Health Organization and average annual number of countries reporting.

Internal hemorrhoids. (Used, with permission, from John Cello, MD.)

Eosinophilic pneumonia

Clinical factors increasing index of suspicion for tuberculosis

Organizing pneumonia (OP)

Development of transfusion-related acute lung injury (TRALI) following blood transfusion. A. Pre transfusion; B. Post-transfusion showing rapid emergence.

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma Kazuya Takamochi, MD, Shiaki Oh, MD,

Pulmonary sarcoidosis

T cell differentiation

Correlation between pulmonary arterial pulse pressure (PP) measured using fluid-filled Swan–Ganz (SG) versus high-fidelity micromanometer-tipped Millar.

Diaphragmatic length–tension curve in normal hamsters and hamsters with elastase-induced emphysema. Tension is expressed as a percentage of maximum tetanic.

(Reproduced with permission from Amato AA, Russell JA

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

REVEAL Registry PAH Risk Score Calculator

(Adapted and reprinted with permission, from Hughes JM et al: Effect of lung volume on the distribution of pulmonary blood flow in man. Respir Physiol.

Fungal histopathology. A. India ink wet mount C. neoformans. B

Internal hemorrhoids. (Used, with permission, from John Cello, MD.)

Volumetric reconstruction of axial magnetic resonance (MR) images in a normal subject (top panel) and a patient with sleep apnea (bottom panel). The mandible.

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

The Hippocrates of Ostia

EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

Schematic representation of main EGFR-TKIs resistance mechanisms.

Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

Matthew D. Hellmann, MD, Boris Reva, PhD, Helena Yu, MD, Valerie W

Detection rate for EGFR mutations in cfDNA.

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Clinical courses of patients.

Detection rate of EGFR mutations in cfDNA by characteristics

(A) Survival time. (A) Survival time. All patients. (a) PFS since the start of EGFR-TKI (groups A, B and C). (b) OS since the start of EGFR-TKI (groups.

Coexistence of Tyrosine Kinase Inhibitor-Sensitizing and Resistant EGFR Mutations in an Untreated Lung Adenocarcinoma Patient and Response to Erlotinib

Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung.

Erratum Journal of Thoracic Oncology

Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy.

EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer Philip C. Mack,

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Aglaya G. Iyevleva, MD, PhD Journal of Thoracic Oncology

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas

Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung.

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone? Alvaro Leone, BSc.D

Daniel B. Costa, MD, PhD, Susan E. Jorge, PhD, Jason P

Modeling of EGFR exon 20 insertions using the 3-dimensional structure of the EGFR kinase domain predicts different interactions with the erlotinib-binding.

Location of common clinically relevant mutations in EGFR

Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure Joel P. Womack,

Patterns of clinical relapse and algorithm for the therapeutic strategy when AR to EGFR TKI occurs in patients with EGFR-mutant NSCLC. *After discussion.

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

Epidermal growth factor receptor (EGFR) mutations in NSCLC Epidermal growth factor receptor (EGFR) mutations in NSCLC. A cartoon representation of EGFR showing the distribution of exons in the epidermal growth factor (EGF) binding and tyrosine kinase domains. Exons 18 to 21 in the tyrosine kinase region where the relevant mutations are located are expanded and the most common mutations associated with drug sensitivity and drug resistance are shown. Source: Lung Cancer, Fishman's Pulmonary Diseases and Disorders, 5e Citation: Grippi MA, Elias JA, Fishman JA, Kotloff RM, Pack AI, Senior RM, Siegel MD. Fishman's Pulmonary Diseases and Disorders, 5e; 2015 Available at: http://accessmedicine.mhmedical.com/DownloadImage.aspx?image=/data/books/1344/p9780071796729-ch108_f004.png&sec=111840555&BookID=1344&ChapterSecID=81197037&imagename= Accessed: October 01, 2017 Copyright © 2017 McGraw-Hill Education. All rights reserved